How Dual-Energy Contrast-Enhanced Spectral Mammography Can Provide Useful Clinical Information About Prognostic Factors in Breast Cancer Patients: A Systematic Review of Literature.

HER2 Ki67 breast cancer: mammography contrast-enhanced spectral mammography estrogen progesterone

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 21 01 2022
accepted: 27 05 2022
entrez: 9 8 2022
pubmed: 10 8 2022
medline: 10 8 2022
Statut: epublish

Résumé

In the past decade, a new technique derived from full-field digital mammography has been developed, named contrast-enhanced spectral mammography (CESM). The aim of this study was to define the association between CESM findings and usual prognostic factors, such as estrogen receptors, progesterone receptors, HER2, and Ki67, in order to offer an updated overview of the state of the art for the early differential diagnosis of breast cancer and following personalized treatments. According to the PRISMA guidelines, two electronic databases (PubMed and Scopus) were investigated, using the following keywords: breast cancer AND (CESM OR contrast enhanced spectral mammography OR contrast enhanced dual energy mammography) AND (receptors OR prognostic factors OR HER2 OR progesterone OR estrogen OR Ki67). The search was concluded in August 2021. No restriction was applied to publication dates. We obtained 28 articles from the research in PubMed and 114 articles from Scopus. After the removal of six replicas that were counted only once, out of 136 articles, 37 articles were reviews. Eight articles alone have tackled the relation between CESM imaging and ER, PR, HER2, and Ki67. When comparing radiological characterization of the lesions obtained by either CESM or contrast-enhanced MRI, they have a similar association with the proliferation of tumoral cells, as expressed by Ki-67. In CESM-enhanced lesions, the expression was found to be 100% for ER and 77.4% for PR, while moderate or high HER2 positivity was found in lesions with non-mass enhancement and with mass closely associated with a non-mass enhancement component. Conversely, the non-enhancing breast cancer lesions were not associated with any prognostic factor, such as ER, PR, HER2, and Ki67, which may be associated with the probability of showing enhancement. Radiomics on CESM images has the potential for non-invasive characterization of potentially heterogeneous tumors with different hormone receptor status. CESM enhancement is associated with the proliferation of tumoral cells, as well as to the expression of estrogen and progesterone receptors. As CESM is a relatively young imaging technique, a few related works were found; this may be due to the "off-label" modality. In the next few years, the role of CESM in breast cancer diagnostics will be more thoroughly investigated.

Identifiants

pubmed: 35941874
doi: 10.3389/fonc.2022.859838
pmc: PMC9355886
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

859838

Informations de copyright

Copyright © 2022 Vasselli, Fabi, Ferranti, Barba, Botti, Vidiri and Tommasin.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Br J Radiol. 2016 Aug;89(1064):20160157
pubmed: 27327403
Breast Cancer Res. 2010;12(4):207
pubmed: 20804570
Breast. 2020 Dec;54:15-24
pubmed: 32889303
Breast Cancer Res. 2012 Jun 14;14(3):R94
pubmed: 22697607
Clin Cancer Res. 2003 Mar;9(3):1039-46
pubmed: 12631604
Radiology. 2015 Aug;276(2):371-80
pubmed: 25965809
NPJ Breast Cancer. 2017 Nov 14;3:43
pubmed: 29152563
Tumori. 2020 Dec;106(6):491-496
pubmed: 32515663
N Engl J Med. 2005 Oct 27;353(17):1773-83
pubmed: 16169887
Semin Ultrasound CT MR. 2018 Feb;39(1):70-79
pubmed: 29317041
J Clin Oncol. 2010 Jan 20;28(3):509-18
pubmed: 19949017
Mol Imaging Biol. 2020 Jun;22(3):780-787
pubmed: 31463822
Nat Rev Clin Oncol. 2017 Oct;14(10):595-610
pubmed: 28561071
Diagnostics (Basel). 2021 Apr 10;11(4):
pubmed: 33920221
Breast J. 2020 May;26(5):860-872
pubmed: 31886607
Clin Radiol. 2017 Dec;72(12):1085.e1-1085.e9
pubmed: 28870431
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Eur Radiol. 2014 Jan;24(1):256-64
pubmed: 24048724
J Med Imaging Radiat Oncol. 2015 Jun;59(3):300-5
pubmed: 25900704
Pathology. 2017 Feb;49(2):166-171
pubmed: 28065411
J Natl Compr Canc Netw. 2018 Mar;16(3):310-320
pubmed: 29523670
Front Oncol. 2021 Feb 22;11:605230
pubmed: 33692950
Clin Imaging. 2021 Jan;69:269-279
pubmed: 33032103
Radiol Med. 2019 Dec;124(12):1229-1237
pubmed: 31773458
Radiology. 2017 Jan;282(1):63-73
pubmed: 27379544
Acad Radiol. 2020 Sep;27(9):1234-1240
pubmed: 31812577
Diagnostics (Basel). 2021 Jul 13;11(7):
pubmed: 34359332
Stud Health Technol Inform. 2005;112:157-66
pubmed: 15923725
Sci Rep. 2020 Jun 17;10(1):9807
pubmed: 32555338
Br J Radiol. 2017 Mar;90(1071):20160717
pubmed: 28055247
Phys Med. 2021 Mar;83:221-241
pubmed: 33951590
AJR Am J Roentgenol. 2006 Nov;187(5):W528-37
pubmed: 17056886
Oncologist. 2004;9(6):606-16
pubmed: 15561805
Eur Radiol. 2011 Mar;21(3):565-74
pubmed: 20839001
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Acad Radiol. 2017 Jan;24(1):89-94
pubmed: 27765597
Diagnostics (Basel). 2020 Sep 17;10(9):
pubmed: 32957690
Biomed Res Int. 2018 Oct 08;2018:6120703
pubmed: 30402486
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Diagnostics (Basel). 2020 Jul 18;10(7):
pubmed: 32708512
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929
Acad Radiol. 2019 Feb;26(2):202-209
pubmed: 29754995

Auteurs

Federica Vasselli (F)

Radiology and Diagnostic Imaging, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy.

Alessandra Fabi (A)

Precision Medicine in Breast Cancer Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.

Francesca Romana Ferranti (FR)

Radiology and Diagnostic Imaging, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy.

Maddalena Barba (M)

Division of Medical Oncology 2, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy.

Claudio Botti (C)

Division of Breast Surgery, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy.

Antonello Vidiri (A)

Radiology and Diagnostic Imaging, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy.

Silvia Tommasin (S)

Human Neuroscience Department, Sapienza University of Rome, Rome, Italy.
Neuroimmunology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione Santa Lucia, Rome, Italy.

Classifications MeSH